Bulletin from the Annual General Meeting 2025
The Annual General Meeting 2025 of RaySearch Laboratories AB (publ) was held on May 22, 2025, in Stockholm, Sweden. The following resolutions were adopted.
STOCKHOLM, May 22, 2025 /PRNewswire/ -- It was resolved to re-elect Carl Filip Bergendal, Johan Löf, Günther Mårder, Britta Wallgren and Hans Wigzell as Board members of the company and to re-elect Hans Wigzell as Chairman of the Board.
The Annual General Meeting adopted the balance sheets and income statements and discharged the members of the Board and the CEO from liability. It was resolved, in accordance with the Board's proposal, on a dividend of SEK 3 per share and that the remaining accumulated profit, amounting to SEK 187,755,281 be brought forward and balanced in the new accounts. The record date for the dividend was determined to be May 26, 2025.
It was resolved that remuneration to Board members who do not receive a salary from any Group company, shall amount to SEK 840,000 to the Chairman of the Board and SEK 300,000 to each of the other Board members elected by the general meeting.
It was resolved, in accordance with the Board's proposal, to re-elect the auditing firm Deloitte AB as auditor for the period until the next Annual General Meeting. Further, it was resolved that the auditor's fees be paid in accordance with approved invoicing.
The Annual General Meeting also resolved to approve the Board's remuneration report for 2024 and to adopt the Board's proposal for guidelines on executive remuneration.
More information and complete documentation relating to the Annual General Meeting is available at www.raysearchlabs.com.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch's software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.
For more information, please contact:Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)Telephone: + 46 (0) 8 510 530 00johan.lof@raysearchlabs.com
Nina Grönberg, CFO, RaySearch Laboratories AB (publ)Telephone: + 46 (0) 8 510 530 00nina.gronberg@raysearchlabs.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/raysearch-laboratories/r/bulletin-from-the-annual-general-meeting-2025,c4154251
The following files are available for download:
https://mb.cision.com/Main/1102/4154251/3466307.pdf
RaySearch Press Release May 22, 2025
View original content:https://www.prnewswire.com/news-releases/bulletin-from-the-annual-general-meeting-2025-302463658.html
SOURCE RaySearch Laboratories
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why Newmont Corporation (NEM) Crashed On Friday
We recently published a list of . In this article, we are going to take a look at where Newmont Corporation (NYSE:NEM) stands against other Friday's worst-performing stocks. Newmont extended its losing streak to a fourth straight day on Friday, losing 3.94 percent to end at $52.36 apiece as investors unloaded positions following the drop in gold prices. On the same day, gold saw its spot prices decline by 1.26 percent to $3,310.42 per troy ounce, amid a profit-taking from the previous day's gains. In the first quarter of the year, Newmont Corporation (NYSE:NEM) achieved a 1,012-percent increase in net income attributable to shareholders in the first quarter of the year, at $1.89 billion versus the $170 million in the same period last year. A gold mine entry with a conveyor belt transporting minerals from the depths of a shaft. Revenues amounted to $5.01 billion, representing an increase of 24 percent from the $4.02 billion in the same period a year earlier. Amid the impressive performance, Newmont Corporation (NYSE:NEM) declared a $0.25 cash dividend to common stockholders as of May 27, payable on June 20. Newmont Corporation (NYSE:NEM) is a leading gold mining company, which also produces copper, zinc, lead, and silver. Overall, NEM ranks 9th on our list of Friday's worst-performing stocks. While we acknowledge the potential of NEM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Why Newmont Corporation (NEM) Crashed On Friday
We recently published a list of . In this article, we are going to take a look at where Newmont Corporation (NYSE:NEM) stands against other Friday's worst-performing stocks. Newmont extended its losing streak to a fourth straight day on Friday, losing 3.94 percent to end at $52.36 apiece as investors unloaded positions following the drop in gold prices. On the same day, gold saw its spot prices decline by 1.26 percent to $3,310.42 per troy ounce, amid a profit-taking from the previous day's gains. In the first quarter of the year, Newmont Corporation (NYSE:NEM) achieved a 1,012-percent increase in net income attributable to shareholders in the first quarter of the year, at $1.89 billion versus the $170 million in the same period last year. A gold mine entry with a conveyor belt transporting minerals from the depths of a shaft. Revenues amounted to $5.01 billion, representing an increase of 24 percent from the $4.02 billion in the same period a year earlier. Amid the impressive performance, Newmont Corporation (NYSE:NEM) declared a $0.25 cash dividend to common stockholders as of May 27, payable on June 20. Newmont Corporation (NYSE:NEM) is a leading gold mining company, which also produces copper, zinc, lead, and silver. Overall, NEM ranks 9th on our list of Friday's worst-performing stocks. While we acknowledge the potential of NEM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
3 hours ago
- Yahoo
Lilly partners with Camurus in search of a long-lasting obesity drug
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Looking to defend its giant cardiometabolic health franchise, Eli Lilly is licensing a technology from Swedish biotechnology firm Camurus that promises to produce longer-acting medications. Camurus' FluidCrystal technology is designed to methodically release a therapeutic drug substance into the body over a period of days or months. After an injection, the solution interacts with bodily fluids to transform into a liquid crystalline gel. The gel holds the active ingredient and then slowly degrades, releasing medicine. The deal includes an unspecified upfront payment as part of an initial package that may be worth as much as $290 million, Camurus said Tuesday. That figure also includes payments for reaching certain development and regulatory milestones. Another $580 million could be available for meeting sales goals, along with mid-single digit royalties for successful products. Lilly and rival Novo Nordisk revolutionized diabetes and obesity treatment over the last few years with GLP-1 medicines that opened up one of the biggest markets the pharmaceutical industry has ever seen. In the first quarter alone, Lilly raked in more than $6 billion from sales of tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity. Novo brought in even more from its Ozempic and Wegovy. Now Lilly and Novo are faced with defending the market as a raft of competitors vie to offer newer and better options. Both companies have bulked up their pipelines; Lilly recently claimed success in a Phase 3 trial of a GLP-1 medicine that can be taken in pill form instead of injection. It also has a triple-acting drug in development and a number of other experimental medicines that work differently. The Camurus deal allows Lilly to apply the long-acting technology to as many as four of its drug compounds. That may help the company stave off competitors such as Metsera, which in January announced promising research for its experimental long-acting GLP-1 shot. Meanwhile, Roche recently announced a $1.65 billion deal to expand its obesity pipeline and Amgen and Viking Therapeutics are both moving into late-stage studies of potential rival treatments. Companies are also working on ways to augment the Lilly and Novo medicines. Veru is testing a drug designed to help preserve muscle when taken with Novo's Wegovy. Regeneron and others are conducting similar research. Recommended Reading Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs
